Oppenheimer Maintains Outperform on DexCom, Lowers Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on DexCom (NASDAQ:DXCM) but lowers the price target from $150 to $115.
July 26, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on DexCom but lowers the price target from $150 to $115.
The Outperform rating suggests continued confidence in DexCom's performance, but the lowered price target indicates some concerns about future growth or market conditions. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100